Diabetes & hormonesLiving with chronic illness

Symptoms and complications of LC-FAODs

Long-chain fatty acid oxidation disorders can cause a number of serious symptoms and complications.

Jan, 20263 min read
LearnEndocrinologyLong chain 3-hydroxyacyl-coa dehydrogenase deficiencySymptoms and complications of LC-FAODs
  • How LC-FOADs affect the body
  • Symptoms and complications

Long-chain fatty acid oxidation disorders (LC-FAODs) are rare metabolic disorders that prevent the body from metabolizing long-chain fatty acids, an important energy source that is found in many different foods, including fish, meat, eggs, dairy, seeds, and nuts. Most people with a LC-FAOD are diagnosed as newborns, but for others, the disease appears later.

Here, we look at some of the symptoms and complications that can result when a person has LC-FAOD.

How LC-FOADs affect the body

Metabolism is the process of converting the food a person ingests into energy. The metabolic process is complex, but the basic idea is that food is broken down into energy molecules that can be transported to cells and used by those cells for energy.

When a person has a LC-FAOD, the body is unable to complete the process of breaking down and converting long-chain fatty acids. As a result, organs and systems throughout the body may not have enough available energy.

Another effect of incomplete metabolism is the buildup of fatty acid intermediates. Fatty acid intermediates are substances that are produced as long-chain fatty acids are metabolized. When the metabolic process is incomplete, these fatty acid intermediates can accumulate in the blood and organs—and if the levels become high enough, it can be toxic to the body.

Symptoms and complications

LC-FAODs can impact many parts of the body and cause a number of symptoms and complications, some of which can be life-threatening. These include:

  • Chronic energy deficiency.
  • Muscle weakness, muscle atrophy, muscle pain, and exercise intolerance.
  • Rhabdomyolysis, a breakdown of muscle tissue that releases proteins into the bloodstream and can cause damage to the kidneys. This may be induced by exercise, fasting, or illness.
  • Neurological complications, including developmental delays and peripheral neuropathy—nerve damage to the extremities that can cause pain, tingling, numbness, and other sensations.
  • Nausea, lack of appetite, cramping, and other gastrointestinal symptoms.
  • Vision loss, including impaired ability to see colors and see in low light, and retinopathy (damage to the blood vessels that supply the eye).
  • Structural changes to the heart that make it more difficult for the heart to pump blood (called cardiomyopathy). This can lead to irregular heartbeat, heart failure, and in some cases, sudden death.
  • Liver dysfunction, including chronic liver disease, enlargement of the liver, and elevated liver enzymes.
  • Hyperammonemia (high levels of ammonia in the body) which can cause seizures, coma, and death.
  • Acidosis, a buildup of acid in the body.
  • Hypoglycemia (very low blood sugar) and hypoketotic hypoglycemia (a combination of low blood sugar and low levels of ketones, which are byproduct of fat metabolism and are another energy source for cells).

Keep in mind that LC-FAODs are a different experience for every person—there are multiple types of LC-FAODs (as well as disorders that affect the metabolism of other fatty acids), and disorders can vary in severity and symptoms.

It is important to talk to you or your family’s healthcare provider about symptoms to watch for, preventing acute episodes of symptoms, and how to seek treatment if an acute episode occurs.

Sources: Jerry Vockley. "Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies." American Journal of Managed Care + 17
  1. Jerry Vockley. "Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies." American Journal of Managed Care, 2020. Vol. 26.
  2. E. Kruger, D. Marsden, J. Black-Shinn, N.A. Thomas and P. McNiven. "Method for Estimating Frequency in Long Chain Fatty Acid Oxidation Disorders and Forecasting Future Trends in the United States." Value in Health, 2020. Vol. 23.
  3. Elahe Abedi and Mohammad Ali Sahari. "Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties." Food Science & Nutrition, 2014. Vol. 2, No. 5.
  4. E. Kruger, D. Marsden, J. Black-Shinn, N.A. Thomas and P. McNiven. "Method for Estimating Disease Frequency in Long Chain Fatty Acid Oxidation Disorders and Forecasting Future Trends in the United States." Value in Health, 2020. Vol. 23.
  5. MedlinePlus. "Metabolic Disorders."
  6. Prabhleen Singh, Scott Culver Thomson and Alicia Ann McDonough. "Metabolic Basis of Solute Transport." Brenner and Rector's The Kidney. Eleventh Edition, 2020.
  7. J. Vockley, B. Burton, et al. "UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24 weeks of treatment." Molecular Genetics and Metabolism, 2017. Vol. 120, No. 4.
  8. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Section 22.4, "Fatty Acids Are Synthesized and Degraded by Different Pathways."
  9. J. Lawrence Merritt 2nd, Erin MacLeod, Agnieszka Jurecka and Bryan Hainline. "Clinical manifestations and management of fatty acid oxidation disorders." Reviews in Endocrine and Metabolic Disorders, 2020.
  10. Jerry Vockley. "Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies." American Journal of Managed Care, 2020. Vol. 26.
  11. Jerry Vockley, Deborah Marsden, et all. "Long-Term Major Clinical Outcomes in Patients With Long Chain Fatty Acid Oxidation Disorders Before and After Transition to Triheptanoin Treatment—A Retrospective Chart Review." Molecular Genetics and Metabolism, 2015. Vol. 116.
  12. MedlinePlus. "Rhabdomyolysis."
  13. Linda De Meirleir and Lance H. Rodan. "Approach to the Patient with a Metabolic Disorder."
  14. Swaiman's Pediatric Neurology, 2017, Vol. 36
  15. National Institute of Neurological Disorders and Stroke. "Peripheral Neuropathy Fact Sheet."
  16. Rimsha Ali and Shivaraj Nagalli. "Hyperammonemia." NCBI StatPearls, 2020.
  17. J. Lawrence Merritt, II, Marie Norris, and Shibani Kanungo. "Fatty acid oxidation disorders." Annals of Translational Medicine, 2018. Vol. 6, No. 24.
  18. Myriad Women's Health. "Carnitine Palmitoyltransferase IA Deficiency."
Written byJameson Kowalczyk.
Medically reviewed byAnn Wendling, MD, MPH.February, 2024
ask-md
AskMD
Questions about managing diabetes?
Written byJameson Kowalczyk.
Medically reviewed byAnn Wendling, MD, MPH.February, 2024
  • How LC-FOADs affect the body
  • Symptoms and complications
ask-md
AskMD
Curious about insulin options?
Sources: Jerry Vockley. "Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies." American Journal of Managed Care + 17
  1. Jerry Vockley. "Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies." American Journal of Managed Care, 2020. Vol. 26.
  2. E. Kruger, D. Marsden, J. Black-Shinn, N.A. Thomas and P. McNiven. "Method for Estimating Frequency in Long Chain Fatty Acid Oxidation Disorders and Forecasting Future Trends in the United States." Value in Health, 2020. Vol. 23.
  3. Elahe Abedi and Mohammad Ali Sahari. "Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties." Food Science & Nutrition, 2014. Vol. 2, No. 5.
  4. E. Kruger, D. Marsden, J. Black-Shinn, N.A. Thomas and P. McNiven. "Method for Estimating Disease Frequency in Long Chain Fatty Acid Oxidation Disorders and Forecasting Future Trends in the United States." Value in Health, 2020. Vol. 23.
  5. MedlinePlus. "Metabolic Disorders."
  6. Prabhleen Singh, Scott Culver Thomson and Alicia Ann McDonough. "Metabolic Basis of Solute Transport." Brenner and Rector's The Kidney. Eleventh Edition, 2020.
  7. J. Vockley, B. Burton, et al. "UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24 weeks of treatment." Molecular Genetics and Metabolism, 2017. Vol. 120, No. 4.
  8. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Section 22.4, "Fatty Acids Are Synthesized and Degraded by Different Pathways."
  9. J. Lawrence Merritt 2nd, Erin MacLeod, Agnieszka Jurecka and Bryan Hainline. "Clinical manifestations and management of fatty acid oxidation disorders." Reviews in Endocrine and Metabolic Disorders, 2020.
  10. Jerry Vockley. "Long-Chain Fatty Acid Oxidation Disorders and Current Management Strategies." American Journal of Managed Care, 2020. Vol. 26.
  11. Jerry Vockley, Deborah Marsden, et all. "Long-Term Major Clinical Outcomes in Patients With Long Chain Fatty Acid Oxidation Disorders Before and After Transition to Triheptanoin Treatment—A Retrospective Chart Review." Molecular Genetics and Metabolism, 2015. Vol. 116.
  12. MedlinePlus. "Rhabdomyolysis."
  13. Linda De Meirleir and Lance H. Rodan. "Approach to the Patient with a Metabolic Disorder."
  14. Swaiman's Pediatric Neurology, 2017, Vol. 36
  15. National Institute of Neurological Disorders and Stroke. "Peripheral Neuropathy Fact Sheet."
  16. Rimsha Ali and Shivaraj Nagalli. "Hyperammonemia." NCBI StatPearls, 2020.
  17. J. Lawrence Merritt, II, Marie Norris, and Shibani Kanungo. "Fatty acid oxidation disorders." Annals of Translational Medicine, 2018. Vol. 6, No. 24.
  18. Myriad Women's Health. "Carnitine Palmitoyltransferase IA Deficiency."

Recommended for you

Endocrinology
What are long-chain fatty acid oxidation disorders?
Article
Endocrinology
Living with FAOD: 5 resources for patients and caregivers
Article
Endocrinology
Long-chain FAODs: talking to your child’s pediatric healthcare team
Article
Hematology
Paroxysmal nocturnal hemoglobinuria: symptoms and complications
Article
Endocrinology
Symptoms of thyroid problems
Article
AskMDHow can I be more consistent?
AskMd LogoAskMd Logo
Privacy policyConsumer health data privacyTerms of use
Cookie policyYour privacy choices

© 2026 Sharecare, Inc.